Ultragenyx Pharmaceutical
RARE
16.48
-0.74
-4.30%
Ultragenyx Pharmaceutical
US · RARE
#3012 by market cap
Listed 1970
16.48
-0.74
-4.30%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:31
Quant vs Street three independent views, side by side
StockVane factor grade
D-
Momentum strategy signal
Strong Sell
Analyst consensus
Buy
Mostly aligned, one view stands apart.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
✦ Quant Analyst Revision Trend how this is computed
Deteriorating
8
■ Upgrades■ Downgrades
- 0 upgrades vs 8 downgrades among tracked analyst rating changes.
- Most recent: RBC Capital moved from Buy to Hold on 2026-10-08.
Analyst consensus 19 analysts
Buy
Avg price target 25.39 +54.1%
Price target rangecurrent 16.48
Low16.00
Avg25.39
High39.00
Buy 47%
Hold 53%
Sell 0%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-11-06 | Citi | -- | Buy | 22.00 |
| 2026-11-06 | H.C. Wainwright | -- | Buy | 25.00 |
| 2026-11-05 | Piper Sandler | -- | Buy | 36.00 |
| 2026-11-05 | Citi | -- | Buy | 22.00 |
| 2026-11-05 | Leerink Partners | -- | Buy | 33.00 |
| 2026-11-05 | H.C. Wainwright | -- | Buy | 25.00 |
| 2026-11-05 | Barclays | -- | Buy | 32.00 |
| 2026-11-04 | TD Cowen | -- | Buy | 19.00 |
| 2026-11-04 | CCORF | -- | Buy | 34.00 |
| 2026-11-04 | BofA Securities | -- | Hold | 20.00 |
| 2026-11-04 | Wedbush | -- | Hold | 22.00 |
| 2026-11-04 | Morgan Stanley | -- | Hold | 22.00 |
| 2026-11-04 | Goldman Sachs | -- | Hold | 17.00 |
| 2026-11-04 | RBC Capital | -- | Hold | 19.00 |
| 2026-11-03 | Cantor Fitzgerald | -- | Buy | 39.00 |
| 2026-11-03 | Wells Fargo | -- | Hold | 19.00 |
| 2026-11-03 | BofA Securities | -- | Hold | 20.00 |
| 2026-10-21 | Piper Sandler | -- | Buy | 36.00 |
| 2026-10-15 | UBS | -- | Hold | 16.00 |
| 2026-10-15 | H.C. Wainwright | -- | Buy | 25.00 |
| 2026-10-14 | UBS | -- | Hold | 16.00 |
| 2026-10-14 | H.C. Wainwright | -- | Buy | 25.00 |
| 2026-10-09 | BofA Securities | -- | Hold | 20.00 |
| 2026-10-08 | H.C. Wainwright | -- | Buy | 25.00 |
| 2026-10-08 | RBC Capital | -- | Hold | 19.00 |
Price target trend monthly average, last 3 years
Recent rating changes
| Date | Firm | Change | Target |
|---|---|---|---|
| 2026-10-08 | RBC Capital | Buy → Hold | 19.00 |
| 2026-09-21 | Evercore | Buy → Hold | 18.00 |
| 2026-09-18 | Morgan Stanley | Buy → Hold | 20.00 |
| 2026-09-18 | Wells Fargo | Buy → Hold | 18.00 |
| 2026-09-18 | BofA Securities | Buy → Hold | 20.00 |
| 2026-09-03 | J.P. Morgan | Buy → Hold | 36.00 |
| 2026-09-02 | William Blair | Buy → Hold | -- |
| 2026-03-24 | Goldman Sachs | Buy → Hold | 25.00 |
Earnings history price reaction on the day
| Period | Report date | Session | Options expected | Actual move |
|---|---|---|---|---|
| 2026/Q3 | 2026-11-03 | After close | ±6.76% | +3.19% (in line) |
| 2026/Q2 | 2026-08-04 | After close | ±19.62% | -3.41% (in line) |
| 2026/Q1 | 2026-05-05 | After close | ±8.84% | +3.68% (in line) |
| 2025/Q4 | 2026-02-12 | After close | ±8.40% | -12.68% (beat) |
| 2025/Q3 | 2025-11-04 | After close | ±11.35% | -1.82% (in line) |
| 2025/Q2 | 2025-08-05 | After close | ±9.32% | -3.01% (in line) |
| 2025/Q1 | 2025-05-06 | After close | ±18.50% | -4.68% (in line) |
| 2024/Q4 | 2025-02-13 | After close | ±13.82% | -2.37% (in line) |
| 2024/Q3 | 2024-11-05 | After close | ±13.99% | -3.18% (in line) |
| 2024/Q2 | 2024-08-01 | After close | ±11.60% | +14.31% (beat) |
| 2024/Q1 | 2024-05-02 | After close | ±9.84% | -1.04% (in line) |
| 2023/Q4 | 2024-02-15 | After close | ±15.02% | +5.75% (in line) |
"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.
Quote time 2026-11-20 19:31:44 · For reference only, not investment advice and not tailored to your situation.
Ultragenyx Pharmaceutical discussion 0 comments